Oragenics logo
Oragenics OGEN
$ 0.16 -5.88%
report update icon

Quarterly report 2026-Q3
added 11-12-2026

Oragenics Net Income | OGEN

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Oragenics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
-984 K -1.06 M -20.7 M -14.3 M -15.7 M -26.4 M -15.6 M -2.76 M -1.46 M -2.67 M -11.7 M -5.79 M -16.1 M -13.1 M -7.68 M -7.81 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-984 K -26.4 M -10.2 M

Quarterly Net Income Oragenics

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-2.6 M -2.53 M -2.2 M - -3.07 M -2.27 M -2.22 M - -2.46 M -2.31 M -2.45 M -12.7 M -2.01 M -3.05 M -2.84 M - -3.87 M -3.59 M -4.59 M - -4.38 M -3.82 M -5.22 M -4.41 M -4.5 M -12.3 M -5.19 M -3.6 M -3.84 M -4.81 M -3.33 M -2.76 M -4.17 M -2.28 M -2.12 M -1.46 M -2.07 M -1.22 M -1.98 M -2.67 M -1.96 M -313 K -2.06 M -2.22 M -1.86 M -6.34 M -1.29 M -1.22 M -1.03 M -1.9 M -1.64 M -3.08 M -9.33 M -2.07 M -1.59 M -1.99 M -2.56 M -6.93 M 1.62 M -1.94 M -1.81 M -2.37 M -1.56 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
1.62 M -12.7 M -3.16 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Albireo Pharma Albireo Pharma
ALBO
-34 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
-241 M - - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
-21.9 M - 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
-41 M - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
-65.2 M - -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
-43.6 M - - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
-46.4 M - - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
-142 M - - $ 127 M usaUSA
Aravive Aravive
ARAV
-76.3 M - -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-61.4 M - - $ 231 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
-465 M $ 84.95 0.13 % $ 7.99 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-26.2 M - 2.71 % $ 14 M usaUSA
Gilead Sciences Gilead Sciences
GILD
8.51 B $ 166.01 -0.31 % $ 207 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
-6.12 M $ 22.14 -1.6 % $ 248 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
27.3 M - - $ 2.02 B usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
-237 M - -0.13 % $ 3.73 B usaUSA
Orgenesis Orgenesis
ORGS
-48.2 M - -33.86 % $ 61.2 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
-152 M - - $ 58.1 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
-44.2 M - -14.27 % $ 1.7 M singaporeSingapore
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-131 M - - $ 86.2 M usaUSA
BELLUS Health BELLUS Health
BLU
-76.1 M - - $ 2.47 B canadaCanada
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
-16.9 M - - $ 13.6 B usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
-141 M - - $ 29.6 M usaUSA
GeoVax Labs GeoVax Labs
GOVX
-4.43 M $ 1.83 -4.45 % $ 8.35 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
-26 M - -33.41 % $ 3.37 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-126 M - - $ 10.1 M usaUSA
Tyme Technologies Tyme Technologies
TYME
-23.6 M - 8.07 % $ 54 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
-434 M - - $ 12.2 B usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
-322 K - -0.89 % $ 114 M usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
-324 M - - $ 309 M usaUSA
Aptinyx Aptinyx
APTX
-64.8 M - -39.0 % $ 4.57 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
-3.59 M - -1.38 % $ 46.8 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
-1.89 M - -0.75 % $ 18.7 M danmarkDanmark
9 Meters Biopharma 9 Meters Biopharma
NMTR
-43.8 M - -42.97 % $ 1.05 M usaUSA
Theratechnologies Theratechnologies
THTX
-8.31 M - - $ 83.9 M canadaCanada
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-10.4 M - 3.16 % $ 1.9 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
-70.8 M - -15.15 % $ 60.3 M britainBritain
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
-21.2 M - -60.05 % $ 125 K usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
-37.2 M - -55.98 % $ 2.15 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
-401 M - - $ 527 M usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
-63.6 M - - $ 121 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
-7.26 M - - $ 521 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
-3.18 M $ 34.99 3.77 % $ 147 M usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
-37.9 M - -47.76 % $ 6.27 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
37.2 M - - - russiaRussia
Kiromic BioPharma Kiromic BioPharma
KRBP
-26.9 M - 6.61 % $ 3.08 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
-195 M - - $ 2.18 B usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
-94.9 M - - $ 1.41 B canadaCanada
Gritstone Oncology Gritstone Oncology
GRTS
-138 M - 0.42 % $ 213 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
-30.4 M - 17.91 % $ 11.1 M usaUSA